Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

Results of CHANCE 2005/CARES-005 study were unveiled by Dr Gao-Jun Teng from Zhongda Hospital, Southeast University, China, ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

A recent study published in The Lancet Respiratory Medicine revealed an increase in lung cancer cases among non-smokers, ...

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

Antihistamine use may improve oncologic and survival outcomes in patients receiving second-line atezolizumab for advanced or metastatic urothelial carcinoma, according to research published in ...

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.